식품 알레르기 진단 및 치료 시장 : 제품 유형, 알레르겐 유형, 연령층, 최종 사용자, 유통 채널별 예측(2026-2032년)

The Food Allergy Diagnostics & Therapeutics Market is projected to grow by USD 14.57 billion at a CAGR of 10.72% by 2032.

Food allergy diagnostics and therapeutics are moving from episodic symptom management toward precision allergy care built on earlier diagnosis, molecular risk stratification, and targeted treatment. The clinical burden is significant: U.S. public health sources report food allergy in approximately 5.8% of children and 6.2% of adults, while global clinical literature consistently identifies rising prevalence, substantial emergency-care utilization, and quality-of-life impact across pediatric and adult populations.

Executive decision-making in this market is shaped by three evidence-based realities. Oral food challenge remains the diagnostic reference standard, but skin-prick testing, serum-specific IgE testing, component-resolved diagnostics, and emerging basophil activation testing are improving the ability to distinguish sensitization from clinically meaningful allergy. On the therapeutic side, avoidance and epinephrine remain foundational, while FDA-approved peanut oral immunotherapy and the 2024 FDA approval of omalizumab for IgE-mediated food allergy have expanded the treatment framework beyond single-allergen desensitization.

Transformative Shifts in the Food Allergy Landscape

The landscape is being reshaped by the convergence of molecular diagnostics, biologic therapy, patient-centered emergency treatment, and stricter allergen-labeling policy. In the United States, sesame became the ninth major food allergen under the FASTER Act in 2023, reinforcing how regulation is influencing testing panels, food manufacturing controls, and patient education. In Europe, mandatory disclosure of 14 regulated allergens continues to shape foodservice, packaged food compliance, and clinical counseling.

Clinically, the market is shifting from broad avoidance advice to quantified risk assessment. Component-resolved diagnostics are helping clinicians evaluate peanut, tree nut, milk, egg, wheat, and shellfish sensitization patterns, while digital symptom tracking and connected care models are improving follow-up. Therapeutics are also diversifying as oral immunotherapy, biologics, epicutaneous approaches, sublingual approaches, and improved epinephrine delivery formats create new opportunities for integrated diagnostic-treatment pathways.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical accelerator across food allergy diagnostics, clinical operations, and therapeutic development. In diagnostics, machine learning can support pattern recognition across serum-specific IgE, component testing, patient history, comorbid asthma, age, atopic dermatitis, and prior reaction severity, helping clinicians prioritize oral food challenges and reduce unnecessary dietary restriction when appropriately validated.

AI also improves trial design and real-world evidence generation by identifying eligible cohorts, modeling responder profiles, and analyzing longitudinal adherence data for oral immunotherapy and biologic use. For industry leaders, the most defensible AI strategies will be those built on transparent algorithms, diverse datasets, clinician oversight, explainable outputs, and compliance with medical device, data privacy, and health equity requirements.

Key Regional Insights Across Global Food Allergy Markets

Asia-Pacific is emerging as a high-priority region as urbanization, dietary diversification, pediatric allergy awareness, and expanding private diagnostics increase demand for IgE testing and specialist allergy services. Japan, China, South Korea, India, and Australia are particularly important because they combine large pediatric populations or mature healthcare systems with rising investment in immunology, digital health, and laboratory infrastructure. Australia also has extensive clinical and public health attention on food allergy due to well-documented pediatric prevalence and national allergy management initiatives.

North America remains the most advanced commercial environment due to high diagnosis rates, established allergist networks, FDA-cleared diagnostic platforms, food-labeling enforcement, school and emergency anaphylaxis protocols, and rapid uptake of approved therapies. Europe is characterized by strong clinical guidelines, the European Union's mandatory labeling of 14 major allergens, established immunology research networks, and broad adoption of evidence-based allergy management through national health systems. Latin America, the Middle East, and Africa are earlier in market maturity, with adoption tied to urban hospital networks, private laboratories, medical tourism hubs, pediatric care expansion, clinician education, and gradual improvements in emergency anaphylaxis preparedness.

Key Group Insights for Strategic Market Expansion

ASEAN markets are gaining relevance as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines expand pediatric care, private diagnostics, and hospital-based allergy services. Demand is strongest where middle-class growth supports specialist consultations and where foodservice globalization increases the need for reliable allergen risk management, packaged food labeling awareness, and school-based emergency response planning.

The GCC is investing in advanced healthcare infrastructure, specialty clinics, and imported diagnostic technologies, creating favorable conditions for premium allergy testing, biologic therapy adoption, and tertiary-care allergy programs. The European Union provides one of the world's most structured allergy environments through harmonized food-labeling rules, pharmacovigilance systems, and guideline-driven care. BRICS economies combine large patient pools with uneven access, making scalable diagnostics, clinician training, and affordable emergency treatment central to growth. G7 countries lead in regulatory sophistication, reimbursement depth, clinical research, and patient advocacy, while NATO-aligned markets benefit indirectly from resilient medical supply chains, emergency preparedness frameworks, and coordinated health security planning.

Key Country Insights in Priority Food Allergy Markets

The United States leads global commercialization through high awareness, FDA oversight, sesame-labeling enforcement, approved peanut oral immunotherapy, and the 2024 approval of omalizumab for one or more IgE-mediated food allergies. Canada has strong public health guidance and specialist care access in urban centers, while Mexico and Brazil represent expanding Latin American opportunities as private diagnostics, pediatric allergy services, and urban hospital capabilities grow.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from robust guideline adoption, established allergology networks, emergency anaphylaxis guidance, and mandatory allergen disclosure, while Russia shows demand in major urban centers despite access variability. China and India offer scale, increasing hospital investment, expanding laboratory capacity, and rising allergy awareness, though access remains uneven outside major cities. Japan, Australia, and South Korea are mature Asia-Pacific markets with strong clinical practice standards, sophisticated diagnostics, established pediatric care pathways, and growing interest in precision immunology.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated care models that connect validated diagnostics, risk stratification, patient education, epinephrine access, and therapy monitoring. Organizations that position testing as a gateway to evidence-based treatment decisions will be better placed than those offering isolated assays or single-point interventions.

Executives should invest in real-world evidence, health-economic studies, and workflow integration for allergists, pediatricians, emergency departments, dietitians, and primary care. Commercial teams should tailor strategies by market maturity: advanced economies require differentiation through precision diagnostics, patient support, and biologic pathway support, while emerging markets need affordable testing, clinician training, cold-chain reliability, supply continuity, and patient education on anaphylaxis recognition.

Research Methodology and Evidence Framework

This executive summary is built from an evidence-led assessment of food allergy diagnostics, therapeutics, regulatory developments, clinical guidelines, public health datasets, and technology adoption patterns. The methodology emphasizes verified sources such as national public health agencies, regulatory authorities, peer-reviewed allergy and immunology literature, clinical trial records, pharmacovigilance updates, and recognized professional guidance.

The analysis triangulates disease burden, diagnostic standards, therapeutic approvals, regional healthcare capacity, allergen-labeling policy, emergency treatment readiness, and commercial adoption conditions. Qualitative insights were structured around clinical utility, reimbursement feasibility, regulatory risk, adoption barriers, health equity, and scalability across hospital, laboratory, specialty clinic, primary care, school, and home-care settings.

Conclusion: Precision Allergy Care Is Defining the Next Phase

Food allergy diagnostics and therapeutics are entering a more sophisticated phase defined by precision testing, approved immunomodulatory therapy, improved emergency treatment options, and data-enabled care pathways. The strongest opportunities sit at the intersection of accurate diagnosis, measurable clinical outcomes, regulatory compliance, and patient-centered treatment access.

Organizations that combine scientific credibility with scalable delivery will be best positioned to lead. Success will depend on validating AI tools, demonstrating cost-effectiveness, supporting clinician adoption, improving patient adherence, and aligning product strategy with regional regulatory, reimbursement, and infrastructure realities.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Food Allergy Diagnostics & Therapeutics Market, by Product Type

• 7.1. Diagnostic Tests
  • 7.1.1. At-Home Allergy Tests
  • 7.1.2. Component Resolved Diagnostics
  • 7.1.3. Skin Prick Tests
  • 7.1.4. Specific IgE Tests
• 7.2. Therapeutic Products
  • 7.2.1. Antihistamines
  • 7.2.2. Emergency Treatments
  • 7.2.3. Immunotherapy
    • 7.2.3.1. Epicutaneous Immunotherapy
    • 7.2.3.2. Oral Immunotherapy
    • 7.2.3.3. Subcutaneous Immunotherapy
  • 7.2.4. Monoclonal Antibodies

8. Food Allergy Diagnostics & Therapeutics Market, by Allergen Type

• 8.1. Egg Allergy
• 8.2. Fish Allergy
• 8.3. Milk Allergy
• 8.4. Peanut Allergy
• 8.5. Sesame Allergy
• 8.6. Shellfish Allergy
• 8.7. Soy Allergy
• 8.8. Tree Nut Allergy
• 8.9. Wheat Allergy

9. Food Allergy Diagnostics & Therapeutics Market, by Age Group

• 9.1. Pediatric
• 9.2. Adults
• 9.3. Geriatric

10. Food Allergy Diagnostics & Therapeutics Market, by End User

• 10.1. Hospital Laboratories
• 10.2. Point-Of-Care Settings
• 10.3. Reference Laboratories
• 10.4. Research Institutes

11. Food Allergy Diagnostics & Therapeutics Market, by Distribution Channel

• 11.1. Clinics & Diagnostic Centers
• 11.2. Hospitals
• 11.3. Online
• 11.4. Pharmacies

12. Food Allergy Diagnostics & Therapeutics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Food Allergy Diagnostics & Therapeutics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Food Allergy Diagnostics & Therapeutics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. ALK-Abello A/S
• 16.2. Allergy Therapeutics plc
• 16.3. bioMerieux SA
• 16.4. DBV Technologies S.A.
• 16.5. Eurofins Scientific SE
• 16.6. HAL Allergy Group
• 16.7. HOB Biotech Group Corp. Ltd.
• 16.8. HYCOR Biomedical
• 16.9. Immunomic Therapeutics Inc.
• 16.10. Lincoln Diagnostics Inc.
• 16.11. Medeca Pharma AB
• 16.12. NEOGEN Corporation
• 16.13. Nestle Health Science S.A.
• 16.14. Omega Diagnostics Group PLC
• 16.15. Pfizer Inc.
• 16.16. Prota Therapeutics Pty Ltd
• 16.17. Quest Diagnostics Incorporated
• 16.18. R-Biopharm AG
• 16.19. Sanofi S.A.
• 16.20. Siemens Healthineers AG
• 16.21. Stallergenes Greer International S.A.
• 16.22. Thermo Fisher Scientific Inc.